Drug Trial Radar · NCT07109726
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
248
Planned (sponsor's estimate)
Start
Sep 23, 2025
Primary completion
Dec 30, 2028
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Terremoto Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Conditions
- Breast Cancer
- Endometrial Cancer
- Ovarian Cancer
- Lung Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
- Solid Tumor
- Cervical Cancer
Interventions
TER-2013Drug
Oral Capsules
Fulvestrant injectionDrug
Fulvestrant 500 mg Intramuscular Injection
TER-2013Drug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients who Experience Dose-Limiting ToxicityTime frame: 28 Days
- Number of patients who experience a treatment-related adverse eventTime frame: Up to 2 years
- Objective Response Rate as assessed by RECIST v1.1Time frame: Up to 2 years
- Duration of Response as assessed by RECIST v1.1Time frame: Up to 2 years
- Progression-Free survival as assessed by RECIST v1.1Time frame: Up to 2 years
- Over-all survival as assessed by RECIST v1.1Time frame: Up to 2 years
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope, Irvine
Irvine, California · Recruiting
Florida Cancer Specialists - Lake Nona
Orlando, Florida · Recruiting
City of Hope, Chicago
Zion, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Mayo Rochester
Rochester, Minnesota · Recruiting
Washington Univ. School of Medicine
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Withdrawn
UH Cleveland Medical Center
Cleveland, Ohio · Recruiting
Sarah Cannon Nashville
Nashville, Tennessee · Recruiting
NEXT Oncology
Austin, Texas · Active not recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START Center for Cancer Research
San Antonio, Texas · Recruiting
START Center for Cancer Research
West Valley City, Utah · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Froedtert & MCW Cancer Center
Milwaukee, Wisconsin · Recruiting
START Dublin, Mater Misericordiae University Hospital
Dublin, Republic of Ireland, Ireland · Not yet recruiting
Centro Clínico Académico de Braga
Braga, Portugal, Portugal · Not yet recruiting
START Lisboa
Lisbon, Portugal, Portugal · Recruiting
PanOncology Trials
San Juan, Puerto Rico · Recruiting
START Research Center at Hospital HM Nou Delfos
Barcelona, Spain, Spain · Recruiting
Hospital Universitario General de Catalunya
Barcelona, Spain, Spain · Recruiting
Md Anderson Cancer Center Madrid-Hospiten
Madrid, Spain, Spain · Not yet recruiting
START Madrid, Fundacion Jimenez Diaz
Madrid, Spain, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.